Mike Mensinger, Chief Product Officer of Beta Bionics, Inc. (NASDAQ:BBNX), filed a Form 4 on October 29, 2026, reporting the sale of 2,650 shares of common stock on October 27, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Mike Mensinger, Chief Product Officer of Beta Bionics, Inc.
  • Transaction: Disposition (code S) of 2,650 shares of common stock on October 27, 2026
  • Sale price: $22 per share, as reported in the filing
  • Remaining ownership: 174,740 shares of common stock held directly following the transaction
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 plan adopted on September 8, 2025, according to the filing
  • Filing method: Signed by Thomas Sohn as Attorney-in-Fact on October 29, 2026

Mensinger's October 2026 Share Sale Under Rule 10b5-1 Plan

According to the Form 4 filed with the SEC on October 29, 2026, Mike Mensinger, who serves as Chief Product Officer of Beta Bionics, Inc. (NASDAQ:BBNX), disposed of 2,650 shares of the company's common stock on October 27, 2026. The shares were sold at a price of $22 each. The filing indicates the transaction was a direct disposition, coded "S" under the reporting instructions.

The filing notes that the sale represents shares sold pursuant to a Rule 10b5-1 plan that Mensinger adopted on September 8, 2025. Such plans, when established in conformance with Rule 10b5-1(c), allow company insiders to set up pre-scheduled trading arrangements in advance. The filing indicates that the transaction box for Rule 10b5-1(c) compliance was checked. Following the reported transaction, Mensinger directly holds 174,740 shares of Beta Bionics common stock, according to the filing.

No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Thomas Sohn as Attorney-in-Fact and submitted on October 29, 2026. No amendment date was listed, indicating this is an original filing rather than a revision.

What Was Disclosed

Beta Bionics Chief Product Officer Mike Mensinger reported selling 2,650 shares of common stock at $22 per share on October 27, 2026, under a Rule 10b5-1 plan adopted September 8, 2025, leaving him with 174,740 shares held directly.